SLS Stock Charges Ahead As AML Trial Buzz Builds: Report Claims Regal Hit 80th Event - Retail Isn’t Convinced

Key Points:

• Sellas Life Sciences' Phase 3 Regal trial for its GPS candidate in acute myeloid leukemia (AML) is nearing the 80-event threshold required for final efficacy analysis, though the company officially reports 78 events to date and has not confirmed recent German media claims.
• The trial aims to demonstrate a median overall survival of 12.6 months for GPS versus eight months for the control group, with final data expected after database lock and statistical review, potentially leading to a Biologics License Application (BLA) submission to the FDA.
• Investor sentiment is cautiously optimistic following positive cancer vaccine data from Moderna, which has boosted expectations for Sellas’ GPS candidate; however, retail investors remain skeptical without official confirmation of the milestone.
• Sellas also plans to release initial data from its Phase 2 SLS009 trial in newly diagnosed AML patients in Q4 2026 and ended Q2 with $138.3 million in cash, despite a widening quarterly net loss.
• Sellas shares surged 15% recently, marking their best weekly performance in nearly two months, and have gained 778% over the past year amid growing anticipation around the company’s clinical catalysts.